Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11159
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHaase, Michaelen
dc.contributor.authorHaase-Fielitz, Anjaen
dc.contributor.authorBellomo, Rinaldoen
dc.contributor.authorMertens, Peter Ren
dc.date.accessioned2015-05-16T00:44:47Z
dc.date.available2015-05-16T00:44:47Z
dc.date.issued2011-01-01en
dc.identifier.citationCurrent Opinion in Hematology; 18(1): 11-8en
dc.identifier.govdoc21102325en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/11159en
dc.description.abstractAcute renal disease has major prognostic impact in hospitalized patients. Early diagnosis using renal function markers such as serum creatinine or urinary output and effective treatment are currently not possible. This review focuses on recent studies examining the biological characteristics and the diagnostic and prognostic value of a novel biomarker, neutrophil gelatinase-associated lipocalin (NGAL), in patients at risk for acute renal disease.NGAL levels increase early and proportional to the degree of renal injury in the urine and plasma. Here, we report the results of clinical studies where NGAL was measured in 325 patients with autoimmune and infectious diseases, those with cisplatin-associated nephrotoxicity, and more than 4000 patients at risk of acute kidney injury due to sepsis, cardiac surgery, exposure to contrast media, or after renal transplantation. Whenever renal damage occurred, as evidenced by histopathology or subsequent increase in serum creatinine levels, NGAL levels were higher than in patients without acute renal disease. An increase in NGAL substantially preceded clinical diagnosis of acute renal disease.NGAL fulfills many characteristics of an appropriate 'real-time' renal biomarker. The data on NGAL could justify re-assessment of the concept and definition of acute kidney injury.en
dc.language.isoenen
dc.subject.otherAcute Kidney Injury.blood.diagnosis.etiology.urineen
dc.subject.otherAcute-Phase Proteins.urineen
dc.subject.otherBiological Markers.blood.urineen
dc.subject.otherHumansen
dc.subject.otherLipocalins.blood.urineen
dc.subject.otherMeta-Analysis as Topicen
dc.subject.otherProto-Oncogene Proteins.blood.urineen
dc.titleNeutrophil gelatinase-associated lipocalin as a marker of acute renal disease.en
dc.typeJournal Articleen
dc.identifier.journaltitleCurrent opinion in hematologyen
dc.identifier.affiliationDepartment of Nephrology and Intensive Care, Charité - University Medicine Berlin, Berlin, Germany bDepartment of Nephrology and Hypertension and Endocrinology and Metabolic Diseases, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany cDepartment of Intensive Care, Austin Hospital, Melbourne, Australiaen
dc.identifier.doi10.1097/MOH.0b013e3283411517en
dc.description.pages11-8en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/21102325en
dc.type.austinJournal Articleen
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
crisitem.author.deptIntensive Care-
crisitem.author.deptData Analytics Research and Evaluation (DARE) Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

6
checked on Jan 29, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.